What is the Y-tunnus number of Avansor Pharma Oy?

Avansor Pharma Oy is registered with PRH / YTJ under Y-tunnus 1835834-2.

What is the revenue of Avansor Pharma Oy?

Avansor Pharma Oy reported revenue of EUR 3,3M in 2025.

Carl-Johan Erik Lindroos is the CEO of Avansor Pharma Oy, in role since 2023.

Hans Gunnar Lindroos chairs the board of Avansor Pharma Oy, in role since 2013.

Avansor Pharma Oy's registered address is Tekniikantie 14.

OYActive

Y-tunnus 1835834-2Tekniikantie 14, 02150 EspooWholesale of pharmaceutical and medical goods· NACE 4646Est. 2003 · 23 years old— employeeswww.avansorpharma.fi

Actively employed in the business

Name	Role	Member since
Current (2)
CE Carl-Johan Erik Lindroos Chief Executive Officer	Chief Executive Officer	2023
EM Eva Maria Lindroos Deputy Member	Deputy Member	2013
Former (1)
RA Ritva Anneli Raitmaa Audit	Audit	2016 – 2024

Non-executive oversight

Name	Role	Member since
Current (1)
HG Hans Gunnar Lindroos Chairperson	Chairperson	2013

As of last annual report

No shareholder data available.

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.